CareLit · DOI-Nachweis · Pneumologie
Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI)
DOI 10.1055/s-0036-1592238
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA De Soyza, T Aksamit, TJ Bandel, M Criollo, JS Elborn, E Operschall, E Polverino, K Winthrop, R Wilson
ZeitschriftPneumologie
Ausgabe10/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: RESPIRE 1, an international Phase III trial, aimed to evaluate if Ciprofloxacin DPI as long-term, intermittent therapy in bronchiectasis patients (non-CF etiology) with ≥2 exacerbations (prior 12 months) and respiratory pathogens reduces exacerbations and improves quality-of-life (QoL). We investigated concomitant treatment use at baseline in different countries. Methods: We analysed preliminary baseline…
Zitieren
Zitierempfehlung
A De Soyza, T Aksamit, TJ Bandel, M Criollo, JS Elborn, E Operschall, E Polverino, K Winthrop, R Wilson (2016) Baseline therapies for Bronchiectasis (non-CF etiology) vary by country – data from the RESPIRE1 trial of Ciprofloxacin Dry Powder for Inhalation (DPI). Pneumologie (10). https://doi.org/10.1055/s-0036-1592238
Mit CareLit weiterarbeiten